FDA’s rejection of the two remaining sunscreen time-and-extent applications, including one for an ingredient available OTC through the new drug application pathway, signals “nothing’s going to get to market” anytime soon through monograph changes, according to an advisor for the Public Access to Sunscreens coalition.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?